Novel 21-aminosteroids Prevent Tumour Associated Neurological Dysfunction

  • W. A. King
  • K. L. Black
  • K. Ikezaki
  • S. Conklin
  • D. P. Becker
Conference paper
Part of the Acta Neurochirurgica book series (NEUROCHIRURGICA, volume 51)


The efficacy of the potent lipid peroxidation inhibitors U-74006F and U-78517F in the treatment of blood-tumour barrier permeability and tumour associated neurological dysfunction was evaluated. Rats with stereotactically implanted Walker 256 tumours were treated with methylprednisolone (MP), U-74006F, U-78517F, or vehicle. (0.05 N HC1) on days 6 through 10 following implantation. Neurologic function and vascular permeability was assessed on day 10. U-74006F and MP were equally effective at preventing neurologic dysfunction compared to control (p <0.01). U-78517F was slightly less effective than U-74006F and MP but was significantly better than vehicle in preventing neurological dysfunction. MP resulted in a significant decrease in tumour vascular permeability (p <0.006) while the lipid peroxidation inhibitors had no effect on permeability.


Vascular Permeability Cerebral Vasospasm Maximal Tumour Diameter Experimental Spinal Cord Injury Tumour Vascular Permeability 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Anderson DK, Braughler JM, Hall ED et al (1988) Effects of treatment with U-74006F on neurological outcome following experimental spinal cord injury. J Neurosurg 69: 562–567PubMedCrossRefGoogle Scholar
  2. 2.
    Blasberg RG, Patlak CS, Jehle JW et al (1978) An autoradiographic technique to measure the permeability of normal and abnormal brain capillaries. Neurology 28: 363Google Scholar
  3. 3.
    Braughler JM, Chase RL, Neff GL et al (1987): A new 21aminosteroid antioxidant lacking glucocorticoid activity stimulates ACTH secretion and blocks arachidonic acid release from mouse pituitary tumour (AtT-20) cells. J Pharmacol Exp Ther 244: 423–427Google Scholar
  4. 4.
    Braughler JM, Hall ED, Jacobsen EJ et al (1989) The 21-aminosteroid, U-74006F, for CNS trauma and ischaemia. Drugs of the Future 14: 143–152Google Scholar
  5. 5.
    Giorgio B, Nadia G, Carletto Z et al (1989) Steroid hormones influence on glioma cells proliferation in vitro. Presented at the Annual Meeting of the American Association of Neurological SurgeryGoogle Scholar
  6. 6.
    Hall ED, Braughler PA, Yonkers KE et al,(1990) U-78517F, a second generation lazaroid with potent antioxidant and cerebroprotective activity in models of CNS injury and ischaemia. J Neurotraume (in press)Google Scholar
  7. 7.
    Hall ED, Pazara KE, Braughler JM (1988) 21-aminosteroid lipid peroxidation inhibitor U-74006F protects against cerebral ischaemia in gerbils. Stroke 19: 997–1002Google Scholar
  8. 8.
    Hall ED, Yonkers PA, McCall JM et al (1988) Effects of the 21aminosteroid U-74006F in experimental head injury in mice. J Neurosurg 68: 456–461PubMedCrossRefGoogle Scholar
  9. 9.
    Hall ED, Travis MA (1988) Effect of the nonglucocorticoid 21aminosteroid U-74006F on acute cerebral hypoperfusion following experimental subarachnoid haemorrhage. Exp Neurol 102: 244–248PubMedCrossRefGoogle Scholar
  10. 10.
    Steinke DE, Weir BKA, Findlay JM et al (1989) A trial of the 21-aminosteroid U-74006F in a primate model of chronic cerebral vasospasm. Neurosurgery 24: 179–186PubMedCrossRefGoogle Scholar
  11. 11.
    Vollmer DG, Kassell NF, Hongo K et al (1989) Effect of the nonglucocoritcoid 21-aminosteroid U-74006F on experimental cerebral vasospasm. Surg Neurol 31: 190–194PubMedCrossRefGoogle Scholar
  12. 12.
    Zuccarello M, Marsch JT, Schmitt G et al (1989) Effect of the 21-aminosteroid U-74006F on cerebral vasospasm following subarachnoid haemorrhage. J Neurosurg 71: 98–104PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • W. A. King
    • 2
  • K. L. Black
    • 1
  • K. Ikezaki
    • 1
  • S. Conklin
    • 1
  • D. P. Becker
    • 1
  1. 1.Brain Research Institute, Jonsson Cancer Center and Division of NeurosurgeryUCLA School of MedicineLos AngelesUSA
  2. 2.Division of Neurosurgery, 74–140 CHSUCLA School of MedicineLos AngelesUSA

Personalised recommendations